320 related articles for article (PubMed ID: 4008930)
1. The serologic response to Meth A sarcoma vaccines after cyclophosphamide treatment is additionally increased by various adjuvants.
Livingston PO; Jones M; Deleo AB; Oettgen HF; Old LJ
J Immunol; 1985 Aug; 135(2):1505-9. PubMed ID: 4008930
[TBL] [Abstract][Full Text] [Related]
2. Comparison of approaches for augmenting the serologic response to the individually specific methylcholanthrene-induced sarcoma-Meth A: pretreatment with cyclophosphamide is most effective.
Livingston PO; DeLeo AB; Jones M; Oettgen HF
J Immunol; 1983 Nov; 131(5):2601-5. PubMed ID: 6631013
[TBL] [Abstract][Full Text] [Related]
3. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells.
Livingston PO; Calves MJ; Natoli EJ
J Immunol; 1987 Mar; 138(5):1524-9. PubMed ID: 3805726
[TBL] [Abstract][Full Text] [Related]
4. Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn.
O'Boyle KP; Zamore R; Adluri S; Cohen A; Kemeny N; Welt S; Lloyd KO; Oettgen HF; Old LJ; Livingston PO
Cancer Res; 1992 Oct; 52(20):5663-7. PubMed ID: 1394190
[TBL] [Abstract][Full Text] [Related]
5. Cross-reacting tumor associated transplantation antigen on primary 3-methylcholanthrene-induced BALB/c sarcomas.
Coggin JH
Mol Biother; 1989; 1(4):223-8. PubMed ID: 2818874
[TBL] [Abstract][Full Text] [Related]
6. Expression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomas.
Palladino MA; Srivastava PK; Oettgen HF; DeLeo AB
Cancer Res; 1987 Oct; 47(19):5074-9. PubMed ID: 3497717
[TBL] [Abstract][Full Text] [Related]
7. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
Mokyr MB; Ye QW
Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
[TBL] [Abstract][Full Text] [Related]
8. Studies of allogeneic tumor transplants: induced rejection of advanced tumors by immune alteration of recipients.
Russell PS; Chase CM; Burton RC
J Immunol; 1983 Feb; 130(2):951-7. PubMed ID: 6336775
[TBL] [Abstract][Full Text] [Related]
9. [Effects of levamisole on methylcholanthrene-induced tumor. I. Its antitumor effect and immunological mechanism].
Gomi K; Morimoto M; Nomoto K
Gan To Kagaku Ryoho; 1982 Jul; 9(7):1262-8. PubMed ID: 7184454
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
Ye QW; Mokyr MB
Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
[TBL] [Abstract][Full Text] [Related]
11. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Borden EC; Sidky YA; Hatcher JF; Bryan GT
Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
[TBL] [Abstract][Full Text] [Related]
12. Serological analysis of cell surface antigens on methylcholanthrene-induced mouse sarcomas with antisera produced against the tumors.
Tanimoto M; Takahashi T; Nishizuka Y
Gan; 1982 Apr; 73(2):184-92. PubMed ID: 6288499
[TBL] [Abstract][Full Text] [Related]
13. Effect of fractional cyclophosphamide dosage on sheep red blood cell-delayed-type hypersensitivity response in mice.
Rondinone SN; Giovanniello OA; Barrios HA; Nota NR
J Immunol; 1983 Apr; 130(4):1600-3. PubMed ID: 6220061
[TBL] [Abstract][Full Text] [Related]
14. [Antitumor effect of human recombinant interferon-alpha A/D in mice(I): Comparison between systemic and lesional treatment of meth-A sarcoma in BALB/c mice].
Nanjo M; Yoshie O; Aso H; Ebina T; Ishida N
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):505-9. PubMed ID: 4004283
[TBL] [Abstract][Full Text] [Related]
15. Factors affecting passive monoclonal antibody therapy of Moloney sarcoma in BALB/c mice.
Kennel SJ; Lankford PK; Flynn KM; Winegar R
Cancer Res; 1985 Aug; 45(8):3782-9. PubMed ID: 2410101
[TBL] [Abstract][Full Text] [Related]
16. Cellular immunity to solubilized tumor antigens of a methylcholanthrene-induced sarcoma with a migration inhibition assay.
Padarathsingh ML; Dean JH; McCoy JL; Lewis DD; Northing JW; Natori T; Law LW
J Immunol; 1978 Jun; 120(6):1981-5. PubMed ID: 659888
[TBL] [Abstract][Full Text] [Related]
17. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
Krosnick JA; Mulé JJ; McIntosh JK; Rosenberg SA
Cancer Res; 1989 Jul; 49(14):3729-33. PubMed ID: 2736513
[TBL] [Abstract][Full Text] [Related]
18. [Effects of levamisole on methylcholanthrene-induced tumor. II. Potentiation of cytotoxic T-cell activities].
Gomi K; Morimoto M; Nomoto K
Gan To Kagaku Ryoho; 1982 Jul; 9(7):1269-76. PubMed ID: 6985196
[TBL] [Abstract][Full Text] [Related]
19. Properties of a M(r) 110,000 tumor rejection antigen of the chemically induced BALB/c Meth A sarcoma.
De Leo AB; Becker M; Lu L; Law LW
Cancer Res; 1993 Apr; 53(7):1602-7. PubMed ID: 7680955
[TBL] [Abstract][Full Text] [Related]
20. Antibody-dependent lymphocyte cytotoxicity in the murine sarcoma virus system: activity of IgM and IgG with specificity for MLV determined antigen(s).
Lamon EW; Skurzak HM; Andersson B; Whitten HD; Klein E
J Immunol; 1975 Apr; 114(4):1171-6. PubMed ID: 1117138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
